These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23407222)

  • 1. The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
    Decloedt EH; Mwansa-Kambafwile J; van der Walt JS; McIlleron H; Denti P; Smith P; Wiesner L; Rangaka M; Wilkinson RJ; Maartens G
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):333-5. PubMed ID: 23407222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.
    Decloedt EH; van der Walt JS; McIlleron H; Wiesner L; Maartens G
    Int J Tuberc Lung Dis; 2015 Oct; 19(10):1194-6. PubMed ID: 26459532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
    Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
    Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
    Chokephaibulkit K; Cressey TR; Capparelli E; Sirisanthana V; Muresan P; Hongsiriwon S; Ngampiyaskul C; Limwongse C; Wittawatmongkol O; Aurpibul L; Kabat B; Toye M; Smith ME; Eksaengsri A; McIntosh K; Yogev R;
    Antivir Ther; 2011; 16(8):1287-95. PubMed ID: 22155910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
    Kredo T; Mauff K; Van der Walt JS; Wiesner L; Maartens G; Cohen K; Smith P; Barnes KI
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5616-23. PubMed ID: 21947399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.
    Fan-Havard P; Liu Z; Chou M; Ling Y; Barrail-Tran A; Haas DW; Taburet AM;
    Antimicrob Agents Chemother; 2013 May; 57(5):2154-60. PubMed ID: 23459477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
    McIlleron H; Denti P; Cohn S; Mashabela F; Hoffmann JD; Shembe S; Msandiwa R; Wiesner L; Velaphi S; Lala SG; Chaisson RE; Martinson N; Dooley KE;
    J Antimicrob Chemother; 2017 Jul; 72(7):2028-2034. PubMed ID: 28419277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
    Prasitsuebsai W; Cressey TR; Capparelli E; Vanprapar N; Lapphra K; Chokephaibulkit K
    Pediatr Infect Dis J; 2012 Apr; 31(4):389-91. PubMed ID: 22146740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
    Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
    HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
    Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
    Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
    Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
    Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
    Chokephaibulkit K; Plipat N; Cressey TR; Frederix K; Phongsamart W; Capparelli E; Kolladarungkri T; Vanprapar N
    AIDS; 2005 Sep; 19(14):1495-9. PubMed ID: 16135903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1.
    Mugabo P; Els I; Smith J; Rabie H; Smith P; Mirochnick M; Steyn W; Hall D; Madsen R; Cotton MF
    S Afr Med J; 2011 Sep; 101(9):655-8. PubMed ID: 21920159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
    Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
    Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.
    Nikanjam M; Kabamba D; Cressey TR; Burger D; Aweeka FT; Acosta EP; Spector SA; Capparelli EV
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5374-80. PubMed ID: 22869579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women.
    Mildvan D; Yarrish R; Marshak A; Hutman HW; McDonough M; Lamson M; Robinson P
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):471-7. PubMed ID: 11981363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.
    Merry C; Barry MG; Mulcahy F; Ryan M; Tjia JF; Halifax KL; Breckenridge AM; Back DJ
    AIDS; 1998 Jul; 12(10):1163-7. PubMed ID: 9677165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.